Unfortunately not, It follows that we set the length of drug patents at a high enough level that, on average, drug companies can continue their work of inventin

Unfortunately not, It follows that we set the length of drug patents at a high enough level that, on average, drug companies can continue their work of inventing drugs. In other words, they will sometimes make a unseemly profit on a monopoly position, but at least the existence of that possibility creates the incentive for development of drugs. The alternative is to kill the whole industry. Sorry - the world is not ideal.